Stavas Mark J, Carlson Matthew L, Attia Albert, Jacobson Gary P, Rivas Alejandro, Morales-Paliza Manuel, Wanna George B
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Am J Otolaryngol. 2014 Sep-Oct;35(5):565-71. doi: 10.1016/j.amjoto.2014.05.002. Epub 2014 May 9.
To date, the majority of the vestibular schwannoma (VS) literature has focused on tumor control rates, facial nerve function and hearing preservation. Other factors that have been shown to significantly affect quality-of-life (QOL), such as dizziness, remain understudied. The primary objective of the current study is to investigate the association between radiation dose to the vestibule and post-treatment changes in vestibular function and patient reported dizziness handicap.
This is a prospective observational pilot study at a tertiary academic referral center including all subjects that underwent linear accelerator-based stereotactic radiotherapy (SRS) for sporadic VS and completed pre-treatment and post-treatment vestibular testing and Dizziness Handicap Inventory (DHI) questionnaires. Associations between objective vestibular test results, patient-reported DHI scores and radiation dose parameters were investigated.
Ten patients met inclusion criteria. Tumor control was achieved in all individuals. There were no statistically significant associations or identifiable trends between radiation dose and change in vestibular function or DHI scores. Notably, the four ears receiving the highest vestibular dose had minimal changes in vestibular function tests and DHI scores.
To the best of our knowledge, no previous reports have described the association between radiation dose to the vestibule and post-treatment changes in vestibular function and patient reported DHI. Based on these preliminary data, radiation dose to the vestibule does not reliably predict change in objective or subjective vestibular outcome measures.
迄今为止,大多数关于前庭神经鞘瘤(VS)的文献都集中在肿瘤控制率、面神经功能和听力保留方面。其他已被证明会显著影响生活质量(QOL)的因素,如头晕,仍未得到充分研究。本研究的主要目的是调查前庭接受的辐射剂量与治疗后前庭功能变化以及患者报告的头晕障碍之间的关联。
这是一项在三级学术转诊中心进行的前瞻性观察性试点研究,纳入了所有接受基于直线加速器的立体定向放射治疗(SRS)的散发性VS患者,并完成了治疗前和治疗后的前庭测试以及头晕障碍量表(DHI)问卷调查。研究了客观前庭测试结果、患者报告的DHI评分与辐射剂量参数之间的关联。
10名患者符合纳入标准。所有个体均实现了肿瘤控制。辐射剂量与前庭功能变化或DHI评分之间没有统计学上的显著关联或可识别的趋势。值得注意的是,接受前庭剂量最高的四只耳朵在前庭功能测试和DHI评分方面变化最小。
据我们所知,以前没有报告描述过前庭接受的辐射剂量与治疗后前庭功能变化以及患者报告的DHI之间的关联。基于这些初步数据,前庭接受的辐射剂量不能可靠地预测客观或主观前庭结果测量的变化。